Clancy Paul J — SEC insider filings
SEC reporting owner CIK 1409601. 53 insider filings on record with FilingPulse; latest filed 2026-11-19.
Transaction summary — filings shown
Covers the 50 most recent of 53 filings on record, filed 2021-04-01 to 2026-11-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 15,000 shares, $1,423,950 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 62.
- Largest priced transaction: sale of 15,000 shares @ $94.93 ($1,423,950) in INCYTE CORP, filed 2026-05-21.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| INCYTE CORP (INCY) | Director | 30 | — | 1 leg · 15,000 sh · $1,423,950 | 37 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | Director | 4 | — | — | 8 |
| EXACT SCIENCES CORP (EXAS) | Director | 7 | — | — | 8 |
| Xilio Therapeutics, Inc. (XLO) | Director | 5 | — | — | 6 |
| Sionna Therapeutics, Inc. (SION) | Director | 2 | — | — | 2 |
| ALIGN TECHNOLOGY INC (ALGN) | Director | 2 | — | — | 1 |
Insider filings — Clancy Paul J
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-19 | 3 | ALIGN TECHNOLOGY INC (ALGN) | Holdings only — no transactions reported | EDGAR |
| 2026-11-19 | 4 | ALIGN TECHNOLOGY INC (ALGN) | Grant/award (A): 903 (derivative) @ $0 | EDGAR |
| 2026-10-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 203 @ $121.35 | EDGAR |
| 2026-07-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 252 @ $113.36 | EDGAR |
| 2026-06-18 | 4 | Sionna Therapeutics, Inc. (SION) | Grant/award (A): 17,340 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | INCYTE CORP (INCY) | Grant/award (A): 1,642 @ $0 · Grant/award (A): 6,111 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | INCYTE CORP (INCY) | Option exercise (M): 15,000 @ $84.53 · Sale (S): 15,000 @ $94.93 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 265 @ $94.12 | EDGAR |
| 2026-03-23 | 4 | EXACT SCIENCES CORP (EXAS) | Disposition to issuer (D): 20,640 · Disposition to issuer (D): 5,398 | EDGAR |
| 2026-01-05 | 4 | INCYTE CORP (INCY) | Grant/award (A): 241 @ $98.77 | EDGAR |
| 2025-10-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 285 @ $84.81 | EDGAR |
| 2025-07-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 361 @ $68.10 | EDGAR |
| 2025-06-16 | 4 | EXACT SCIENCES CORP (EXAS) | Grant/award (A): 5,398 @ $0 | EDGAR |
| 2025-06-16 | 4 | Sionna Therapeutics, Inc. (SION) | Grant/award (A): 19,959 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,518 @ $0 · Grant/award (A): 9,216 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 358 @ $60.55 | EDGAR |
| 2025-01-03 | 4 | INCYTE CORP (INCY) | Grant/award (A): 331 @ $69.07 | EDGAR |
| 2024-12-20 | 4/A | EXACT SCIENCES CORP (EXAS) | Grant/award (A): 5,939 @ $0 | EDGAR |
| 2024-10-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 368 @ $66.10 | EDGAR |
| 2024-07-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 399 @ $60.62 | EDGAR |
| 2024-06-17 | 4 | EXACT SCIENCES CORP (EXAS) | Grant/award (A): 5,444 @ $0 | EDGAR |
| 2024-06-17 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,830 @ $0 · Grant/award (A): 12,517 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 403 @ $56.97 | EDGAR |
| 2024-01-03 | 4 | INCYTE CORP (INCY) | Grant/award (A): 412 @ $62.79 | EDGAR |
| 2023-10-03 | 4 | INCYTE CORP (INCY) | Grant/award (A): 379 @ $57.77 | EDGAR |
| 2023-07-05 | 4 | INCYTE CORP (INCY) | Grant/award (A): 380 @ $62.25 | EDGAR |
| 2023-06-16 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,505 @ $0 · Grant/award (A): 11,294 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 13,200 (derivative) @ $0 | EDGAR |
| 2023-06-12 | 4 | EXACT SCIENCES CORP (EXAS) | Grant/award (A): 3,599 @ $0 | EDGAR |
| 2023-04-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 318 @ $72.27 | EDGAR |
| 2023-01-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 294 @ $80.32 | EDGAR |
| 2022-10-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 339 @ $66.64 | EDGAR |
| 2022-07-01 | 4 | INCYTE CORP (INCY) | Grant/award (A): 321 @ $75.97 | EDGAR |
| 2022-06-23 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/award (A): 4,975 (derivative) @ $0 · Grant/award (A): 29,307 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | INCYTE CORP (INCY) | Grant/award (A): 2,144 @ $0 · Grant/award (A): 9,124 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 13,200 (derivative) @ $0 | EDGAR |
| 2022-06-13 | 4 | EXACT SCIENCES CORP (EXAS) | Grant/award (A): 5,606 @ $0 | EDGAR |
| 2022-05-24 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 1,585 @ $0 · Option exercise (M): 1,585 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 326 @ $79.42 | EDGAR |
| 2022-01-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 343 @ $73.40 | EDGAR |
| 2021-10-26 | 4 | Xilio Therapeutics, Inc. (XLO) | Grant/award (A): 44,033 (derivative) @ $0 · Grant/award (A): 65,528 (derivative) @ $0 | EDGAR |
| 2021-10-04 | 4 | INCYTE CORP (INCY) | Grant/award (A): 321 @ $68.78 | EDGAR |
| 2021-07-02 | 4 | EXACT SCIENCES CORP (EXAS) | Grant/award (A): 2,567 @ $0 | EDGAR |
| 2021-07-02 | 4 | INCYTE CORP (INCY) | Grant/award (A): 283 @ $84.13 | EDGAR |
| 2021-06-02 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Option exercise (M): 1,686 @ $0 · Option exercise (M): 1,686 (derivative) @ $0 | EDGAR |
| 2021-05-28 | 4 | INCYTE CORP (INCY) | Grant/award (A): 1,923 @ $0 · Grant/award (A): 8,010 (derivative) @ $0 | EDGAR |
| 2021-05-24 | 4 | AGIOS PHARMACEUTICALS, INC. (AGIO) | Grant/award (A): 1,585 (derivative) @ $0 · Grant/award (A): 8,888 (derivative) @ $0 | EDGAR |
| 2021-04-01 | 4 | INCYTE CORP (INCY) | Grant/award (A): 298 @ $81.27 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-04 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1409601 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs